FOR INFLAMMATION + PAIN RELIEF
This extra strength formula comes with a whopping 2000 mg. Extra relief is added with the raw CBDA included. Research has confirmed that together these cannabinoids act as anti-inflammatories, which is the main source of pain. To increase the benefits, we blended in Alpha-Pinene, Beta-caryophyllene and Bisabol terpenes because of their own anti-inflammatory properties. All mixed together this fierce Wave is a must have for staying active.
2000mg per bottle
(1000mg CBDA + 500mg CBN + 500mg CBG)
Smaller Dose, Greater Impact
0.25ml = 8mg CBDA + 4mg CBD + 4mg CBN
*Also available in a convenient mini size.
scroll to learn more
Expertly crafted in-house by our team of scientists and professionals this tincture will have you tackling the different pains life throws at you. Research into CBD (cannabidiol), CBG (cannabigerol), and CBDA (the raw precursor to cannabidiol) proved them to be effective anti-inflammatories. With CBG specifically targeting nerve discomfort and inflammation. CBG has also been studied for its benefits on digestive health and gut inflammation and has become a go-to for people suffering from IBS (irritable bowel syndrome).
Another reason to reach for our pain-free formula is that CBDA is absorbed up to 11 times better than CBD, which can help you consume lower doses. Alpha-pinene (Rosemary), Beta-caryophyllene (black pepper) and Bisabolol (chamomile) are a hardworking trio of naturally derived terpenes used as an analgesic (relieves pain) by their anti-inflammatory and antioxidant properties.
Sources https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922297/ https://pubmed.ncbi.nlm.nih.gov/31881765/ https://dmd.aspetjournals.org/content/36/9/1917.long •R Mechoulam et al. Hashish. IV. The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids. Tetrahedron 1965 May;21(5):1223-9 •Borrelli, Francesca, et al. Biochemical pharmacology 85.9 (2013): 1306-1316. •Formukong, E. A., A. T. Evans, and F. J. Evans. Inflammation 12.4 (1988): 361-371. •Pellesi, L., et al. European Journal of Clinical Pharmacology 74.11 (2018): 1427-1436. https://pubmed.ncbi.nlm.nih.gov/20157878/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920849/ https://pubmed.ncbi.nlm.nih.gov/23138934/ https://pubmed.ncbi.nlm.nih.gov/26119957/ https://pubmed.ncbi.nlm.nih.gov/30864870/